Metamizol Zentiva (Metamizole Sodium Monohydrate)

Metamizol Zentiva belongs to the pyrazolone class and is indicated for conditions that require strong analgesic or antipyretic therapy.

• Pain (moderate to severe): provides effective analgesia when weaker agents are insufficient.
• Fever: lowers elevated body temperature in acute febrile states.
• Acute postoperative pain: helps control pain following surgical procedures.

• Metamizole exerts its effect primarily through inhibition of cyclooxygenase enzymes, which reduces prostaglandin synthesis, and by modulating central pain pathways in the spinal cord and brain. The exact mechanism is not fully elucidated, but the combined peripheral and central actions contribute to its analgesic and antipyretic properties.

Metamizol may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Nausea: mild to moderate stomach upset.
• Vomiting: occasional emesis after dosing.
• Dizziness: transient light‑headedness.
• Headache: mild cranial discomfort.
• Skin rash: mild erythema or pruritus.
• Hypotension: occasional drop in blood pressure.

Serious or Rare Side Effects

• Agranulocytosis: severe reduction in white blood cells, potentially life‑threatening.
• Stevens‑Johnson syndrome: severe skin and mucous membrane reaction.
• Anaphylaxis: acute allergic response with airway compromise.
• Hepatotoxicity: liver enzyme elevation or injury.
• Blood dyscrasias: other abnormal blood cell counts.
• Severe hypotension: marked drop in blood pressure requiring medical intervention.

Before initiating therapy with Metamizol Zentiva, several safety considerations should be observed.

• Baseline blood count: obtain complete blood count to detect pre‑existing neutropenia.
• Monitor infection signs: watch for fever or sore throat indicating possible agranulocytosis.
• Renal impairment: adjust use in patients with reduced kidney function.
• Hypersensitivity: avoid if the patient has known allergy to pyrazolones.
• Medical supervision: use only under physician direction.
• Store at ambient temperature: keep in the original packaging, protect from moisture and direct sunlight.

Metamizol Zentiva can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

• Concurrent myelosuppressive agents: may amplify risk of severe blood cell depletion.
• Other NSAIDs or pyrazolones: increase likelihood of agranulocytosis and gastrointestinal irritation.
• Anticoagulants: may enhance bleeding tendency.

Moderate Interactions (Monitor Closely)

• Alcohol: can potentiate central nervous system depression and gastric irritation.
• Diuretics: may affect electrolyte balance and renal clearance of Metamizol.